1. Home
  2. CRDF vs DAVA Comparison

CRDF vs DAVA Comparison

Compare CRDF & DAVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Cardiff Oncology Inc.

CRDF

Cardiff Oncology Inc.

SELL

Current Price

$0.87

Market Cap

67.1M

Sector

Health Care

ML Signal

SELL

Logo Endava plc (each representing one)

DAVA

Endava plc (each representing one)

HOLD

Current Price

$1.18

Market Cap

80.3M

Sector

Technology

ML Signal

HOLD

Company Overview

Basic Information
Metric
CRDF
DAVA
Founded
1999
2000
Country
United States
United Kingdom
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
EDP Services
Sector
Health Care
Technology
Exchange
Nasdaq
Nasdaq
Market Cap
67.1M
80.3M
IPO Year
2012
2015

Fundamental Metrics

Financial Performance
Metric
CRDF
DAVA
Price
$0.87
$1.18
Analyst Decision
Buy
Hold
Analyst Count
5
5
Target Price
★ $5.14
$3.63
AVG Volume (30 Days)
★ 1.0M
286.0K
Earning Date
11-12-2026
12-01-2026
Dividend Yield
N/A
N/A
EPS Growth
★ 27.37
N/A
EPS
N/A
★ N/A
Revenue
★ $365,993.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$1.70
P/E Ratio
★ N/A
$20.02
Revenue Growth
★ 49.61
N/A
52 Week Low
$0.71
$1.16
52 Week High
$3.31
$7.18

Technical Indicators

Market Signals
Indicator
CRDF
DAVA
Relative Strength Index (RSI) N/A N/A
Support Level N/A N/A
Resistance Level N/A N/A
Average True Range (ATR) 0.00 0.00
MACD 0.00 0.00
Stochastic Oscillator 0.00 0.00

Price Performance

Historical Comparison
CRDF
DAVA

About CRDF Cardiff Oncology Inc.

Cardiff Oncology Inc is a clinical-stage biotechnology company advancing cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Its main asset, onvansertib, is a specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (mCRC), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, to overcome treatment resistance and deliver improved clinical outcomes for patients.

About DAVA Endava plc (each representing one)

Endava is a next-generation IT services company that primarily assists clients with their digital transformation efforts by creating customized software for them. The company was founded in 2006 in the UK, and it continues to generate the majority of revenue in the UK and Europe. Endava's client base is concentrated in the payments and financial services, technology, media, and telecom industries.

Share on Social Networks: